Pharmaceutical Group Sues US Government Over Medicare Drug Pricing Rule
MT newswire2026/10/07 17:4301:43 PM EDT, 10/07/2026 (MT Newswires) -- The Pharmaceutical Research and Manufacturers of America said Wednesday it filed a lawsuit against the US government seeking to vacate Medicare's most favored nation drug pricing policy, alleging that it is unlawful and exceeds Centers for Medicare & Medicaid Services' authority. The complaint filed in the US District Court for the District of Columbia challenges the GLOBE rule, which requires drug manufacturers to pay rebates to the CMS that effectively limit Medicare Part B drug prices to benchmarks based on prices in 19 OECD countries, according to a statement. The group said the rule would provide minimal patient benefit, with only 0.3% of Medicare Part B beneficiaries expected to benefit from lower out-of-pocket costs, and could reduce investment in research and development. The group argued that the policy imposes nationwide price-setting policies without congressional authorization and raises constitutional concerns. The Department of Health and Human Services did not immediately respond to MT Newswires' request for comment. Price: 142.80, Change: +0.86, Percent Change: +0.61
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
French political turmoil hits the euro, hedge fund short bets reach more than six-year high
As the political turmoil in France continues to unsettle the European bond market and drag down the euro’s performance, hedge funds are increasing their bearish bets on the euro.
The US will exempt some Canadian goods from tariffs, involving nine categories of products including packaging materials and machinery.
Susan Collins, a Republican Senator from Maine, stated on Friday that the US government will grant tariff exemptions for certain Canadian imports.
SK Hynix abandons Solidigm US IPO plan; analysts say future NAND supply will decrease, benefiting Micron and SanDisk
The analyst team at LYNX Equity Strategies pointed out that if Solidigm's IPO funds had been used to expand NAND capacity in the US, it could have increased global supply after three years or more, thereby putting downward pressure on pricing. Now that this financing channel is closed, the associated risk has disappeared, which is a substantial positive for both Micron and SanDisk; however, for Intel, it is a minor negative, as it means losing a potential manufacturing project.
Crypto prices
More
